Scholarlink

Background <p>Radioligand therapy is an important treatment option for neuroendocrine neoplasms. Although the use of internal dosimetry is recommended, its application in clinical routine is not widespread. This study aims to propose and evaluate a feasible method for determining the absorbed doses to organs at risk and tumour lesions in a large cohort of neuroendocrine neoplasm patients. Eighty patients who were treated as part of the FENET-2016 trial were enrolled in this study prospectively. The FENET-2016 protocol is based on two therapeutic schemes: a MONO therapy, consisting of five administrations (therapeutic cycles) of 177Lu-DOTATOC and a DUO therapy, consisting of three cycles of 177Lu-DOTATOC alternating with two cycles of 90Y-DOTATOC. A simplified method based on three-time-point SPECT/CT was first validated on a small cohort of patients and was then applied to all the eighty patients enrolled in the study to assess dosimetric evaluation for the organs at risk (kidneys, bone marrow, and tumours).</p> Results <p>Sixty-nine patients underwent a complete dosimetric evaluation. Absorbed doses per administered activity and cumulative absorbed doses were reported for organs at risk and tumours, as well as biologically effective doses for organs at risk. The results of this study are consistent with published data from other groups. The cumulative absorbed dose to the kidneys exceeded the threshold reported in the literature in ten cases out of sixty-nine cases, while no cases of a cumulative absorbed dose exceeding 2 Gy to the bone marrow were reported. High variability in tumour absorbed dose per unit activity was observed. </p> Conclusions <p>The proposed simplified dosimetric approach is feasible and easy to implement in clinical practice. This study demonstrated that dosimetry is a useful clinical tool, as it enables clinicians to guide patients towards combined radionuclide treatment or multiple treatments, which could improve patient outcomes.</p> Clinical trial registration <p>- EU Clinical Trials Register, EUDRACT Id: 2016-005129-35, 22 February 2018.</p> Trial registration <p>EUDRACT 201,600,512,935, Registered 22 February 2018, https//www.clinicaltrialsregister.eu/ctrsearch/search? query=2016-005129-35.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Emerging need of dosimetry in radioligand therapy: a feasible method tested in a large cohort of patients affected by neuroendocrine neoplasms

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月21日

查看全文
  • Mariaconcetta Longo,
  • Eugenia Tonini,
  • Giovanni Di Domenico,
  • Lorenzo Longo,
  • Christian Macis,
  • Ilaria Panzini,
  • Licia Uccelli,
  • Alessandro Turra,
  • Luca Urso,
  • Corrado Cittanti,
  • Mirco Bartolomei

摘要

Background

Radioligand therapy is an important treatment option for neuroendocrine neoplasms. Although the use of internal dosimetry is recommended, its application in clinical routine is not widespread. This study aims to propose and evaluate a feasible method for determining the absorbed doses to organs at risk and tumour lesions in a large cohort of neuroendocrine neoplasm patients. Eighty patients who were treated as part of the FENET-2016 trial were enrolled in this study prospectively. The FENET-2016 protocol is based on two therapeutic schemes: a MONO therapy, consisting of five administrations (therapeutic cycles) of 177Lu-DOTATOC and a DUO therapy, consisting of three cycles of 177Lu-DOTATOC alternating with two cycles of 90Y-DOTATOC. A simplified method based on three-time-point SPECT/CT was first validated on a small cohort of patients and was then applied to all the eighty patients enrolled in the study to assess dosimetric evaluation for the organs at risk (kidneys, bone marrow, and tumours).

Results

Sixty-nine patients underwent a complete dosimetric evaluation. Absorbed doses per administered activity and cumulative absorbed doses were reported for organs at risk and tumours, as well as biologically effective doses for organs at risk. The results of this study are consistent with published data from other groups. The cumulative absorbed dose to the kidneys exceeded the threshold reported in the literature in ten cases out of sixty-nine cases, while no cases of a cumulative absorbed dose exceeding 2 Gy to the bone marrow were reported. High variability in tumour absorbed dose per unit activity was observed.

Conclusions

The proposed simplified dosimetric approach is feasible and easy to implement in clinical practice. This study demonstrated that dosimetry is a useful clinical tool, as it enables clinicians to guide patients towards combined radionuclide treatment or multiple treatments, which could improve patient outcomes.

Clinical trial registration

- EU Clinical Trials Register, EUDRACT Id: 2016-005129-35, 22 February 2018.

Trial registration

EUDRACT 201,600,512,935, Registered 22 February 2018, https//www.clinicaltrialsregister.eu/ctrsearch/search? query=2016-005129-35.